Mesenchymal stem cells for cardiac regenerative therapy.

Area of Science:

• Regenerative Medicine
• Cardiovascular Biology
• Stem Cell Therapy

Background:

• The heart was traditionally considered a post-mitotic organ, with limited capacity for self-repair after injury.
• Recent scientific advancements suggest the potential for cardiac regeneration, challenging this long-held view.
• Bone marrow-derived mesenchymal stem cells (MSCs) emerged as a key cell type for investigating cardiac regeneration.

Purpose of the Study:

• To review the biological characteristics of mesenchymal stem cells (MSCs).
• To summarize experimental animal studies and early clinical trials involving MSCs for cardiac repair.
• To discuss cell delivery methods, tracking, and the mechanisms underlying MSC action in myocardial infarction.

Main Methods:

• Review of existing literature on mesenchymal stem cells (MSCs) in cardiac regeneration.
• Analysis of data from preclinical animal models of myocardial infarction (MI).
• Evaluation of early-phase clinical trial outcomes using MSCs for heart disease.

Main Results:

• Therapeutic delivery of MSCs has demonstrated safety and efficacy in improving heart function post-MI in animal studies and early clinical trials.
• MSCs exhibit cardio-protective effects through signaling molecules and possess the potential to differentiate into cardiac and vascular cells.
• MSCs offer practical advantages for cell therapy, including ease of acquisition, expansion, and an immunoprivileged status.

Conclusions:

• Mesenchymal stem cells (MSCs) represent a promising cell source for therapeutic interventions in cardiac diseases.
• The multi-lineage potential and immunomodulatory properties of MSCs support their role in cardiac repair and regeneration.
• Further research into delivery routes, tracking, and mechanisms is crucial for optimizing MSC-based cardiac therapies.